1. Adolescent cognitive function and incident early-onset type 2 diabetes. (November 2021) Authors: Lutski, Miri; Zucker, Inbar; Bardugo, Aya; Bendor, Cole D.; Derazne, Estela; Tzur, Dorit; Novick, Deborah; Raz, Itamar; Pinhas-Hamiel, Orit; Mosenzon, Ofri; Afek, Arnon; Gerstein, Hertzel C.; Twig, Gilad; Cukierman-Yaffe, Tali Journal: EClinicalMedicine Issue: Volume 41(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial. Issue 1 (January 2022) Authors: Lee, Matthew M.Y.; Kristensen, Søren L.; Gerstein, Hertzel C.; McMurray, John J.V.; Sattar, Naveed Journal: Diabetes & metabolic syndrome Issue: Volume 16:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Issue 7 (18th August 2020) Authors: Willeit, Peter; Tschiderer, Lena; Allara, Elias; Reuber, Kathrin; Seekircher, Lisa; Gao, Lu; Liao, Ximing; Lonn, Eva; Gerstein, Hertzel C.; Yusuf, Salim; Brouwers, Frank P.; Asselbergs, Folkert W.; van Gilst, Wiek; Anderssen, Sigmund A.; Grobbee, Diederick E.; Kastelein, John J.P.; Visseren, Fran... Journal: Circulation Issue: Volume 142:Issue 7(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial. Issue 10 (29th June 2022) Authors: Hramiak, Irene; Gerstein, Hertzel C.; Leiter, Lawrence A.; Yale, Jean‐François; Bajaj, Harpreet S.; Stewart, John; Toutounji, Marie‐Josée; Harris, Stewart B. Journal: Diabetes, obesity & metabolism Issue: Volume 24:Issue 10(2022) Page Start: 1998 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Consensus report: Definition and interpretation of remission in type 2 diabetes. Issue 3 (30th August 2021) Authors: Riddle, Matthew C.; Cefalu, William T.; Evans, Philip H.; Gerstein, Hertzel C.; Nauck, Michael A.; Oh, William K.; Rothberg, Amy E.; le Roux, Carel W.; Rubino, Francesco; Schauer, Philip; Taylor, Roy; Twenefour, Douglas Journal: Diabetic medicine Issue: Volume 39:Issue 3(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Issue 1 (14th July 2017) Authors: Gerstein, Hertzel C.; Colhoun, Helen M.; Dagenais, Gilles R.; Diaz, Rafael; Lakshmanan, Mark; Pais, Prem; Probstfield, Jeffrey; Riddle, Matthew C.; Rydén, Lars; Xavier, Denis; Atisso, Charles M.; Avezum, Alvaro; Basile, Jan; Chung, Namsik; Conget, Ignacio; Cushman, William C.; Franek, Edward; Han... Journal: Diabetes, obesity & metabolism Issue: Volume 20:Issue 1(2018) Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Design and baseline characteristics of the AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist. Issue 2 (22nd October 2020) Authors: Gerstein, Hertzel C.; Branch, Kelley; Heenan, Laura; Del Prato, Stefano; Khurmi, Nardev S.; Lam, Carolyn S. P.; Pratley, Richard; Rosenstock, Julio; Sattar, Naveed Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 2(2021) Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial. (20th September 2022) Authors: Branch, Kelley R.H.; Dagenais, Gilles R.; Avezum, Alvaro; Basile, Jan; Conget, Ignacio; Cushman, William C.; Jansky, Petr; Lakshmanan, Mark; Lanas, Fernando; Leiter, Lawrence A.; Pais, Prem; Pogosova, Nana; Raubenheimer, Peter J.; Ryden, Lars; Shaw, Jonathan E.; Sheu, Wayne H.H.; Temelkova‐Kurkts... Journal: European journal of heart failure Issue: Volume 24:Number 10(2022) Page Start: 1805 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). Issue 1 (2nd January 2018) Authors: Gerstein, Hertzel C.; Jung, Hyejung; Rydén, Lars; Diaz, Rafael; Gilbert, Richard E.; Yusuf, Salim Journal: Circulation Issue: Volume 137:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. (October 2017) Authors: Yates, Tom; Davies, Melanie J.; Jung, Hyejung; Bosch, Jackie; Spinas, Giatgen A.; Sreenan, Seamus; Commerford, Patrick; Gerstein, Hertzel C. Journal: Diabetes research and clinical practice Issue: Volume 132(2017) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗